ImmunoBiochem Corporation
Improving patient outcomes through innovations in biological therapeutics
Improving patient outcomes through innovations in biological therapeutics
ImmunoBiochem Corporation is a biotechnology company based in Ontario, Canada, dedicated to revolutionizing cancer treatment by developing targeted biological therapeutics. Founded in 2007, the company has positioned itself at the forefront of innovation in the health care industry.
With a mission to enhance patient outcomes, ImmunoBiochem has harnessed its expertise in cancer research to create cutting-edge tumor microenvironment-targeted antibody-drug conjugates (ADCs). These ADCs represent a groundbreaking class of therapeutics that effectively target cancer cells while minimizing harm to healthy tissue, providing a crucial solution to the challenge of cancer heterogeneity in solid tumors.
Though specific details regarding the latest round of investment are not available, the company has secured a Seed Round investment as of 11 December 2017. ImmunoBiochem's innovative approach to cancer treatment and its commitment to addressing unmet medical needs positions it as a promising prospect within the biotechnology sector, offering potential for significant impact and growth within the health care industry.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | Unknown | - | 11 Dec 2017 | |
| Seed Round | Unknown | - | 18 Apr 2016 |
No recent news or press coverage available for ImmunoBiochem Corporation.
We care about your data, and we'd love to use cookies make your experience better.